搜索结果
靶点ID:TCMBANKGE014572
靶点别名:MSA; TDH2A; TPX
靶点描述:thyroid peroxidase
染色体:2
染色体位置:2p25.3
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:12015
OMIM_Link:606765
Ensembl_Link:ENSG00000115705
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN003780 | iodo tyrosine | C9H10INO3 | 307.08 g/mol | C1=CC(=CC=C1CC(C(=O)O)NI)O | |
| TCMBANKIN009942 | Docosahexaenoic acid(DHA) | C22H32O2 | 328.5 g/mol | CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O | |
| TCMBANKIN012801 | docosahexaenoic acid | DHA; docosahexaenoic acid | C7H10O8 | 222.15 g/mol | C1C(C(C(OC1(C(=O)O)O)C(=O)O)O)O |
| TCMBANKIN014203 | 7-Methyltridecane | NSC59169; Tridecane, 7-methyl-; 26730-14-3 | C14H30 | 198.39 | CCCCCCC(C)CCCCCC |
| TCMBANKIN019832 | Cysteine | C3H7NO2S | 121.16 g/mol | C(C(C(=O)[O-])[NH3+])S | |
| TCMBANKIN025806 | Phenyl isothiocyanate | Phenyl isothiocyanate, reagent grade, 98%; Ylothane; PHENYL ISOTHIOCYANATE; CCRIS 3144; I0191; phenyl-isothiocyanate; iso-thiocyana-tobenaene; WLN: SCNR; RP20215; SC-25756; Jsp000376; ZB008168; AKOS000119287; PITC; PubChem18702; NSC5583; AM90356; Phenyl isothiocyanate, for HPLC derivatization, the detection of alcohols and amines, >=99.0%; TIMTEC-BB SBB040940; MCULE-4369838098; benzene, isothiocyanato; 30342-EP2311817A1; 71255-EP2295418A1; CAS-103-72-0; 30342-EP2311464A1; ST50214555; SCHEMBL20984; AKOS BBS-00004438; 30342-EP2311816A1; TRA0069149; InChI=1/C7H5NS/c9-6-8-7-4-2-1-3-5-7/h1-5; F2121-0322; Fenylisothiokyanat [Czech]; I01-1988; KS-00000V7I; phenyl isothio-cyanate; RTR-000864; 103-72-0; AI3-09310; DTXSID0021129; KSC492K1J; A800790; NSC-5583; KB-59552; phenyl isothiocynate; J-802269; CJ-02152; UNII-0D58F84LSU; AC1L1PAO; Phenyl isothiocyanate solution; MFCD00004798; Benzene,isothiocyanato-; AS04391; phenylisothiocynate; 4-12-00-00867 (Beilstein Handbook Reference); CHEMBL309036; Phenylsenfoel; QKFJKGMPGYROCL-UHFFFAOYSA-N; OTAVA-BB 1055672; Phenyl isothiocyanate, 97% 100g; phenyl isothiocyanate; BBL027476; TR-000864; EINECS 203-138-1; CHEBI:85103; 1-Isothiocyanatobenzene; BRN 0471392; isothiocyanato-benzen; Phenyl thioisocyanate; NCGC00258680-01; Fenylisothiokyanat; USAF M-4; J-801008; 71255-EP2308833A2; Phenyl isothiocyanate solution, 5% in heptane; R522; 30342-EP2308858A1; BDBM50073665; ZINC164500; Tox21_201128; isothiocynato benzene; Phenylisothiocyanate; STL281854; NCGC00248931-01; Phenyl mustard oil; EN300-17278; C7H5NS; DSSTox_RID_75960; Phenyl isothiocyanate, Sigma Grade, 8.36 M, suitable for solid phase protein sequencing analysis, >=99% (GC), liquid; Phenyl isothiocyanate, for protein sequence analysis, >=99.5% (GC); J-523934; CTK3J2514; AN-24653; MolPort-000-145-939; DSSTox_GSID_21129; EDMAN'S REAGENT; Phenyl isothiocyanate, 99%, for protein sequencing; ACMC-20ajx2; Isothiocyanato-benzene; phenyisothiocyanate; Isothiocynatobenzene; LS-7649; Isothiocyanic acid phenyl ester; Phenyl sothocyanate; 0D58F84LSU; FT-0627519; 30342-EP2284157A1; BB_SC-9412; Benzene-1-isothiocyanate; DSSTox_CID_1129; Phenylsenfoel [German]; AC1Q7EXY; SBB040940; Thiocarbanil; CS-B1640; AC1Q7EXX; Phenyl isothiocyanate solution, for protein sequence analysis, ~5% in heptane; NE10354; Benzene, isothiocyanato-; Isothiocyanatobenzene; NSC 5583; Isothiocyanic acid, phenyl ester | C7H5NS | 135.19 | C1=CC=C(C=C1)N=C=S |
| TCMBANKIN032313 | phthalate | C8H4O4-2 | 164.11 g/mol | C1=CC=C(C(=C1)C(=O)[O-])C(=O)[O-] | |
| TCMBANKIN035162 | thyroglobulin | 0 | |||
| TCMBANKIN041402 | chlorogenic acid | 3-methyl-1,4,5-tris(oxidanyl)cyclohexane-1-carboxylic acid; 4-prop-1-enylbenzene-1,2-diol; A821421; 4-prop-1-enylbenzene-1,2-diol; 1,3,4-trihydroxy-5-methyl-1-cyclohexanecarboxylic acid; chlorogenic acid ; Chlorogenic acid; chlorogenicacid | C16H18O9 | 354.309 | C1([H])([H])[C@](C(O[H])=O)(O[H])C([H])([H])[C@@]([H])(OC(=O)\C([H])=C([H])/c2c([H])c([H])c(O[H])c(O[H])c2[H])[C@]([H])(O[H])[C@@]1([H])O[H] |
| TCMBANKIN044727 | salicylic acid | 3320-EP2298732A1; D00097; CCRIS 6714; 3320-EP2287148A2; 3320-EP2298735A1; o-Hydroxybenzoate anion; Trans-Ver-Sal; Verrugon; CHEBI:30762; STK258681; 2y7w; salicylate; BBL000698; 3320-EP2305260A1; 3320-EP2311796A1; K 537; Keralyt; AC1L1JPL; Salicylate anion; 3320-EP2301534A1; Orthohydroxybenzoic acid; 3320-EP2292595A1; o-hydroxybenzoic acid; Salicylate ion; 3320-EP2298777A2; ACS No 10; Ionil; 3320-EP2289871A1; Salicylic acid [USAN:JAN]; 3320-EP2298748A2; SMR000059163; AC1Q5BFS; o-Carboxyphenol; NCGC00178624-02; 3320-EP2269991A2; 25496-36-0; 3320-EP2292614A1; 3320-EP2311451A1; Salicylic acid; YGSDEFSMJLZEOE-UHFFFAOYSA-M; 3320-EP2284179A2; Benzoic acid, 2-hydroxy-; 3320-EP2287150A2; MLS000069653; 3320-EP2301912A2; CHEBI:16914; Ionil-Plus; Salicylic acid & Sulfur Soap; 3320-EP2305637A2; 3320-EP2298743A1; 3320-EP2284151A2; 54-21-7 (SODIUM SALT); AB00053542_03; Salicylic acid collodion; Kyselina 2-hydroxybenzoova [Czech]; Salicylic acid (6CI,8CI); AIDS-006789; 3320-EP2295416A2; KBio2_003996; 2-hydroxy-benzoate; Dr. Scholl's Corn Removers; 3320-EP2284152A2; Advanced Pain Relief Corn Removers; 3320-EP2284156A2; NCGC00159447-02; 3320-EP2316835A1; 3320-EP2295413A1; 3320-EP2308863A1; 3320-EP2292593A2; 3320-EP2305671A1; AIDS006789; Duofil Wart Remover; 2-Hydroxybenzoic acid; 3gf2; InChI=1/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10; 3320-EP2269985A2; C00805; 3twp; 3320-EP2311798A1; 3320-EP2275420A1; hydroxybenzoate; WLN: QVR BQ; Salonil; S7401_SIGMA; NSC 180; Salicylic acid (JP15/USP); 3320-EP2301927A1; 3198-EP2289876A1; 3320-EP2316470A2; NCGC00178624-03; Saligel; 2-HYDROXYPHENYLFORMATE; salicylicacid; CPD-110; 3320-EP2284150A2; Spectrum_000948; EPA Pesticide Chemical Code 076602; 3320-EP2284164A2; 3320-EP2295550A2; SMP2_000145; Acidum salicylicum; CAS_54-21-7; Dr. Scholl's Callus Removers; Stri-Dex; ZB000360; SAL; o-Hydroxybenzoate; 3320-EP2280008A2; Clear away Wart Remover; 3320-EP2295432A1; S8519_SIGMA; CTK5I4917; CJ-00055; Salicylic acid, tech.; Salicylic acid soap; 3320-EP2269978A2; 2-Hydroxybenzoate (Na+); Benzoic acid, 2-hydroxy-, ion(1-); SGCUT00012; Duoplant; Freezone; 3320-EP2284155A2; Occlusal; 3320-EP2284178A2; 3320-EP2301914A1; 3320-EP2311825A1; MFCD00984876; Psoriacid-S-Stift; 3320-EP2301913A1; Rutranex; IDI1_000301; 3320-EP2314578A1; 2-Hydroxybenzenecarboxylic acid; 3320-EP2298765A1; 3320-EP2308832A1; MolPort-003-710-545; 8052-31-1; o-Hydrobenzoate; Retarder W; Salicylic acid-ring-UL-14C; 2y7k; Duofilm; o-Hydrobenzoic Acid; NSC_5900; EINECS 200-712-3; NCGC00159447-04; BDBM85513; 3320-EP2295419A2; 3320-EP2314295A1; STK372903; 63-36-5; 3320-EP2311835A1; DivK1c_000301; 2-Hydroxybenzoic acid ion(1-); 3320-EP2316450A1; 3320-EP2277875A2; Dr. Scholl's Wart Remover Kit; 105910_ALDRICH; HSDB 672; 69-72-7; 3320-EP2311842A2; 2y7p; 3320-EP2284153A2; AI3-02407; 3320-EP2272847A1; 7681-06-3; Phenol-2-carboxylic acid; AKOS005447222; 3198-EP2298777A2; Ionil Plus; KBioSS_001428; 3320-EP2301916A2; T7104; 3320-EP2284170A1; 3320-EP2298764A1; Caswell No. 731; 2-Oxylatobenzoate; 84210_FLUKA; KBio1_000301; 3320-EP2311799A1; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; to_000004; Compound w; 3320-EP2275102A1; 3320-EP2311797A1; 2-Hydroxybenzoate; Kyselina salicylova [Czech]; S5922_SIGMA; 3320-EP2287140A2; 2-Hydroxybenzoic acid anion; 3320-EP2305688A1; 3320-EP2305243A1; UPCMLD-DP126:001; 3320-EP2295412A1; 27301_SIAL; Salicylic acid, ion(1-); 3320-EP2292590A2; 3320-EP2277876A1; W398500_ALDRICH; Oprea1_040343; KBio2_006564; Salicylic acid (TN); Sebucare; 2-Carboxyphenol; Benzoic acid, 2-hydroxy- (9CI); Acido salicilico [Italian]; KBio2_001428; Acido o-idrossibenzoico [Italian]; Advanced Pain Relief Callus Removers; LS-144344; NINDS_000301; 2-hydroxybenzoic acid; 247588_SIAL; 2-CARBOXYBENZENOLATE; 3198-EP2314295A1; NSC180; Domerine; Sebulex; BRN 0774890; CMC_13852 | C7H6O3 | 138.12 | C1=CC=C(C(=C1)C(=O)O)[O-] |
| TCMBANKIN058196 | 4-hydroxy cinnamic acid;trans- p- hydroxy cinnamic acid;trans-p-coumaric acid;p-cumaric acid;4-coumaric acid;P-hydroxy- cinnamic acid;Hydroxycinnamic acid | 4-hydroxycinnamic acid;trans-p-Hydroxycinnamic acid; Trans-p-hydroxy cinnamic acid;AS03322; I01-9546; I01-9648; Para-Coumaric acid; trans-p-Hydroxycinnamate; UNII-IBS9D1EU3J; 4-Hydroxycinamic acid; AK134594; AM20050138; trans-4-Hydroxycinnamic acid; Hydroxycinnamic acid; p-Coumaric acid, primary pharmaceutical reference standard; (E)-3-(4-Hydroxyphenyl)-2-propenoic acid; beta-[4-Hydroxyphenyl]acrylic acid; MP-2217; BP-13278; F2191-0188; IBS9D1EU3J; p-coumaric-acid; STL163567; BG00601173; 2-propenoic acid, 3-(4-hydroxyphenyl)-, (2E)-; 50940-26-6; TR-023948; p-Cumarate; Naringeninic acid; p-Cumaric acid; NCGC00246974-01; (E)-3-(4-Hydroxyphenyl)acrylic acid; CHEBI:36090; AS-12000; N1817; p-Coumaric acid,trans; TL8005115; 501-98-4; bmse010208; bmse000150; TIMTEC-BB SBB007613; DTXSID6064660; p-coumaric acid; NSC-674321; SCHEMBL39106; AKOS 221-47; AC1Q71H0; bmse000591; p-Coumaric acid, trans; MolPort-000-860-894; AE-562/40414679; COUMARIC ACID, TRANS-P-; 4-coumaric acid, (E)-isomer; trans-4-hydroxycinnamate; trans-p-Coumarinic acid; 3-(4-Hydroxyphenyl)-2-propenoate; (E)-3-(4-HYDROXY-PHENYL)-ACRYLIC ACID; LS30305; 3-(4-hydroxyphenyl)acrylic acid; (2E)-3-(4-hydroxyphenyl)prop-2-enoic acid; hydroxycinnamate; 4'-Hydroxycinnamate; SC-25929; trans-p-Hydroxycinnamic acid; (E)-p-Hydroxycinnamic acid; 3-(4-hydroxyphenyl)acrylate; PubChem24323; LS-54111; NGSWKAQJJWESNS-ZZXKWVIFSA-N; trans-4-coumaric acid; trans-p-Cumaric Acid; trans-p-Coumaric acid; AKOS BAR-2479; RTR-023948; RP09062; ZINC39811; 4-10-00-01005 (Beilstein Handbook Reference); 0C1BFF2D-2CF7-4FC1-9F76-3268C2C7F783; LS-54112; C00811; (2E)-3-(4-hydroxyphenyl)acrylic acid; ST2402517; Cinnamic acid, 4-hydroxy-, trans-; BG01501541; 4qem; BDBM4374; HMS1409E10; BRN 2207383; SC-65982; I04-0102; C9H8O3; (E)-3-[4-hydroxyphenyl]-2-propenoic acid; ATTERCOP-CHM AT113965; beta-(4-Hydroxyphenyl)acrylic acid; Para coumaric acid; BCP9001042; MLS001066419; p-Hydroxyphenylacrylic acid; Cinnamic acid, p-hydroxy-; RARECHEM BK HW 0163; 4-Coumaric acid; CS-W020394; TR-017943; p-Coumaric acid, >=98.0% (HPLC); (2E)-3-(4-Hydroxyphenyl)-2-propenoic acid; b-[4-Hydroxyphenyl]acrylate; Q-100560; 7400-08-0; BB_NC-2249; RP17402; BBL012226; AK-26304; W-104438; D0AU0M; p-hydroxycinnamic acid (M4); 2-Propenoic acid, 3-(4-hydroxyphenyl)-, homopolymer; SBB007613; 4-Hydroxycinnamate; ZX-AT011614; Cinnamic acid, p-hydroxy-, (E)-; p-Caumaric acid dehydrogenation homopolymer; SMR000112201; 4f8j; 0-10-00-00297 (Beilstein Handbook Reference); (E)-p-Coumaric acid; 4CN-0926; p-Hydroxycinnamate; (E)-4-hydroxycinnamic acid; 2-Propenoic acid, 3-(4-hydroxyphenyl)-; DB04066; trans-p-Coumaric acid, analytical standard; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, (Z)-; .beta.-[4-Hydroxyphenyl]acrylic acid; p-Coumaricacid; AJ-08911; p-Hydroxy-cinnamic acid; 4-Hydroxy cinnamate; AC1LCUFZ; AKOS000120685; BR-26304; InChI=1/C9H8O3/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-6,10H,(H,11,12)/b6-3; Para coumarate; trans-p-coumarate; 4-Hydroxyphenylpropenoate; P-HYDROXYL CINNAMIC ACID; OTAVA-BB 7020400347; AC-10318; (E)-3-(4-hydroxyphenyl)prop-2-enoic acid; AN-287; LABOTEST-BB LT03329617; p-Hydroxycinnamic acid; MolPort-004-288-351; EINECS 231-000-0; p-Hydroxycinnamic acid, trans; KB-72564; TC-164240; BRN 2207381; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, (E)-; ST24022578; 4-hydroxy cinnamic acid; NSC 674321; LABOTEST-BB LT00452637; Para-Coumarate; (2E)-3-(4-Hydroxyphenyl)-2-propenoic acid #; b-[4-Hydroxyphenyl]acrylic acid; 4'-hydroxycinnamic acid; beta-[4-Hydroxyphenyl]acrylate; NSC-59260; PubChem8247; 4-Hydroxycinnamic acid; CHEMBL66879; CHEBI:32374; BG01501540; NSC674321; RTR-017943; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, (E)- (9CI); NSC59260; 400H080; AX8022446; 3-(4-Hydroxyphenyl)-2-propenoic acid; AC1Q5T95; 3-(4-hydroxyphenyl)prop-2-enoic acid; ST093691; GTPL5787; 4-coumarate; MFCD00004399; NSC 59260;p-hydroxy-cinnamic acid;p- hydroxycinnam icacid; p-hydroxycinnami cacid; p-hydroxy cinnamic acid; p-hydroxycinnamic acid | C9H8O3 | 164.16 g/mol | C1=CC(=CC=C1C=CC(=O)O)O |
| TCMBANKIN058241 | tyrosin;DTY | Benzenepropanoic acid, alpha-amino-4-hydroxy-, (S)-; HSDB 2003; AIDS192306; L-Phenylalanine-4-hydroxy-; EINECS 200-460-4; 4-Hydroxy-L-phenylalanine; Tyrosine (VAN); alpha-Amino-4-hydroxybenzenepropanoic acid, (S)-; AI3-09055; beta-(p-Hydroxyphenyl)alanine; nchembio816-comp11; AIDS192301; AIDS192308; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; CHEBI:17895; AIDS-192301; TYR NH3+ COOH; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; Tyrosinum [Latin]; (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid; AIDS-192307; 25619-78-7; L-Tyrosine (9CI); 1991-85-1; L-Tyrosine, homopolymer; AIDS018692; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; L-Tyrosin; 55520-40-6; Tirosina [Spanish]; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; BB_NC-1194; D00022; C00082; Tyrosine, L- (8CI); Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; Tyrosine [USAN:INN]; T3754_SIAL; 140-43-2; NCGC00159350-03; T8566_SIGMA; AIDS-192305; AIDS-018692; 2-Amino-3-(4-hydroxyphenyl)propanoic acid, (S)-; AIDS-192308; AIDS-192306; 2-Amino-3-(4-hydroxyphenyl)propanoic acid-(S)-; 93829_FLUKA; alpha-Amino-p-hydroxyhydrocinnamic acid, (-)-; (S)-Tyrosine; T4321_SIAL; L-Tyrosine, monomer; L-Tyrosine (JAN); Propanoic acid, 2-amino-3-(4-hydroxyphenyl)-(S)-; NCGC00159350-02; AIDS192305; W373605_ALDRICH; 46209-14-7; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; Tyrosine (USP/INN); FEMA No. 3736; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; NSC 82624; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; AIDS192307; (S)-3-(p-Hydroxyphenyl)alanine | C9H11NO3 | 181.19 g/mol | C1=CC(=CC=C1CC(C(=O)O)N)O |
| TCMBANKIN058288 | catechol | 430749_ALDRICH; Catechin (phenol); Pyrokatechin [Czech]; NCGC00015283-01; Catechol-UL-14C; NCI-C55856; CI Oxidation Base 26; CHEBI:18135; benzene-1,2-diol; C15571; 120-80-9; InChI=1/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8; C9510_SIAL; Fouramine PCH; 135011_SIAL; Lopac-C-9510; 2-hydroxyphenol; NSC 1573; NCGC00091262-01; Fourrine 68; o-Diphenol; C.I. Oxidation Base 26; o-Dioxybenzene; C00090; ST5214346; (1,2,3,4,5,6-(1)?C?)BENZENE-1,2-DIOL; AB-131/40235236; Lopac0_000280; ortho-Benzenediol; Catechol (phenol); ortho-Hydroquinone; ZINC00330145; 16474-90-1; pyrocatechol; benzenediol; Brenzcatechin; 12385-08-9; C01785; EINECS 204-427-5; EU-0100280; nchembio801-comp10; o-Dihydroxybenzene; Durafur Developer CFouramine PCH; o-Hydroxyphenol; Phthalhydroquinone; 16474-89-8; Catechol-pyrocatechol; CCRIS 741; ACM19481108; AI3-03995; Pyrocatechinic acid; CI 76500; Durafur developer C; o-Phenylenediol; 1,2-dihydroxybenzene; ortho-Hydroxyphenol; Oxyphenic acid; BRN 0471401; c0097; pyrocatechol-ul-14C; CAQ; 37349-32-9; ortho-Dihydroxybenzene; AIDS-108194; C3561_SIAL; o-Benzenediol; ortho-Dioxybenzene; Katechol [Czech]; Pelagol Grey C; Pyrokatechol [Czech]; AIDS108194; Pyrocatechinic acidPyrocatechol; WLN: QR BQ; Pyrocatechine; 1,2-benzenediol; o-Hydroquinone; CATECHOL; Benzene, o-dihydroxy-; pyrocatechin; ortho-Phenylenediol; HSDB 1436; C9593_SIGMA; NSC1573; C.I. 76500;pyrocatechol;o-hydroquinone;o-phenylenediol;1,2-benzenediol | C6H6O2 | 110.11 g/mol | C1=CC=C(C(=C1)O)O |
| TCMBANKIN058339 | 3-PhenylpropionicAcid | hydrocinnamic acid; Benzenepropanoic acid; HCI; phenylpropionic acid; InChI=1/C9H10O2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H,10,11; Benzenepropionic acid; Dihydrocinnamic acid; 4-09-00-01752 (Beilstein Handbook Reference); 135232_ALDRICH; W288918_ALDRICH; 3-phenylpropionic acid; BETA-PHENYLPROPIONIC ACID; CCRIS 3199; Hydrocinnamic acid (8CI); NSC9272; Benzenepropanoic acid; AI3-00892; FEMA No. 2889; 56670_FLUKA; .beta.-Phenylpropionic acid; Phenylpropanoic acid; AIDS-110926; 501-52-0; 3-Phenylpropanoic acid; beta-Phenylpropioic acid; Benzylacetic acid; Phenylpropionic acid; C05629; BRN 0907515; NSC 9272; ST5308541; Phenylpropanoate; 3-Phenyl-propionic acid; EINECS 207-924-5; AIDS110926 | C9H10O2 | 150.17 g/mol | C1=CC=C(C=C1)CCC(=O)O |
| TCMBANKIN058486 | Heriguard | Cyclohexanecarboxylic acid, 3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-, [1S-(1alpha,3beta,4alpha,5alpha)]-; Chlorogenic acid (8CI); Cyclohexanecarboxylic acid, 3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-, [1S-(1.alpha.,3.beta.,4.alpha.,5.alpha.)]-; SDCCGMLS-0066467.P001; 202650-88-2; ACon1_000581; (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)-1-oxoprop-2-enoxy]-1,4,5-trihydroxy-1-cyclohexanecarboxylic acid; NSC407296; C00852; [1S-(1alpha,3beta,4alpha,5alpha)]-3-[[3-(3,4-Dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; Chlorogenic acid hemihydrate; Spectrum5_000733; (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxycyclohexane-1-carboxylic acid; 3-[[3-(3,4-Dihydroxyphenyl)-1-oxo-2-propenyl]oxy] 1,4,5-trihydroxycyclohexanecarboxylic acid; CHEBI:16112; C12209; Prestwick0_000427; CCRIS 1400; Prestwick3_000427; (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxy-cyclohexane-1-carboxylic acid; EINECS 206-325-6; Cyclohexanecarboxylic acid, 3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-, (1S,3R,4R,5R)-; Prestwick2_000427; 3-Caffeoylquinic acid; BSPBio_000414; DivK1c_007053; KBio1_001997; BPBio1_000456; (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid; SMP1_000066; KBio2_002354; KBio2_004922; AIDS-012116; C3878_SIGMA; Caffeoyl quinic acid; SPECTRUM210800; (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)acryloyl]oxy-1,4,5-trihydroxy-cyclohexane-1-carboxylic acid; 25700_FLUKA; trans-5-O-Caffeoyl-D-quinate; 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate); SPBio_001836; BSPBio_003353; KBio3_002855; (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; BB_NC-1939; NSC70861; NSC 407296; Chlorogenic acid; Chlorogenate; Cyclohexanecarboxylic acid, 3-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-1,4,5-trihydroxy-, (1S-(1-alpha,3-beta,4-alpha,5-alpha))-; Spectrum3_001797; 1,3,4,5-Tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate; Spectrum2_001898; AIDS012116; Spectrum_001846; 3-O-Caffeoylquinic acid; SPBio_002353; KBio2_007490; 5-O-(3,4-Dihydroxycinnamoyl)-L-quinic acid; cyclohexanecarboxylic acid, 3-[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-, (1S,3R,4R,5R)-; Prestwick_112; KBioSS_002357; NSC 70861; 3-(3,4-Dihydroxycinnamoyl)quinic acid; Prestwick1_000427; Hlorogenic acid; (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)-1-oxoprop-2-enoxy]-1,4,5-trihydroxy-1-cyclohexanecarboxylic acid; (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxy-cyclohexane-1-carboxylic acid; [1S-(1alpha,3beta,4alpha,5alpha)]3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; SpecPlus_000957; (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)acryloyl]oxy-1,4,5-trihydroxy-cyclohexane-1-carboxylic acid; 3-O-(3,4-Dihydroxycinnamoyl)-D-quinic acid; 327-97-9; Chlorogenic acid (8CI); (+)-Chlorogenic acid; ZINC2138728; AJ-33519; SDCCGMLS-0066467.P001; 3-(3,4-Dihydroxycinnamoyl)quinate; Hoodia Chinese Extract; [1S-(1alpha,3beta,4alpha,5alpha)]-3-[[3-(3,4-Dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; NCGC00168941-03; AK-49688; CCRIS 1400; 3-CQ; 3-Caffeoylquinic acid; (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxy-cyclohexanecarboxylic acid; BPBio1_000456; Chlorogenic acid (constituent of echinacea angustifolia root, echinacea pallida root, echinacea purpurea root and echinacea purpurea aerial parts) [DSC]; 3-[3-(3,4-Dihydroxy-phenyl)-acryloyloxy]-1,4,5-trihydroxy-cyclohexanecarboxylic acid; UNII-318ADP12RI; 5-Caffeoylquinic acid; BB_NC-1939; (1S,3R,4R,5R,E)-3-(3-(3,4-dihydroxyphenyl)acryloyloxy)-1,4,5-trihydroxycyclohexanecarboxylic acid; CHLOROGENIC ACID; Cyclohexanecarboxylic acid, 3-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-1,4,5-trihydroxy-, (1S,3R,4R,5R)-; 3-O-Caffeoylquinic acid; Caffetannic acid; Chlorogenic acid [MI]; ALBB-030169; 202650-88-2; CCG-38471; Cyclohexanecarboxylic acid, 3-(((2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl)oxy)-1,4,5-trihydroxy-, (1S,3R,4R,5R)-; C00852; trans-5-O-Caffeoylquinic acid; HMS1923C11; MLS002153805; trans-5-O-caffeoyl-D-quinate; MolPort-035-394-873; CHEBI:16112; 3-[[3-(3,4-Dihydroxyphenyl)-1-oxo-2-propenyl]oxy] 1,4,5-trihydroxycyclohexanecarboxylic acid; SMR000857273; Prestwick2_000427; Chlorogenic acid [WHO-DD]; SR-01000946600-1; Chlorogenic acid, European Pharmacopoeia (EP) Reference Standard; MCULE-8135887819; SR-01000841185; ACT03375; SPECTRUM210800; edit(1S,3R,4R,5R)-3-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexane-1-carboxylic acid; SR-01000946600; (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylicacid; PubChem13036; 3-[(E)-3-(3,4-Dihydroxy-phenyl)-acryloyloxy]-1,4,5-trihydroxy-cyclohexanecarboxylic acid; Chlorogenate; AC1LX54Y; (1S,3R,4R,5R)-3-[(E)-3-(3,4-DIHYDROXY-PHENYL)-ACRYLOYLOXY]-1,4,5-TRIHYDROXY-CYCLOHEXANECARBOXYLIC ACID; Chlorogenic?acid; Quinic acid, 3-caffeoyl-, E-; NCGC00168941-01; AC-6032; AKOS015955866; 32CF6D13-8F08-485F-B79E-F8A6AC318E07; (1S,3R,4R,5R)-3-((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)-1,4,5-trihydroxycyclohexanecarboxylic acid; Cyclohexanecarboxylic acid, 3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-, [1S-(1alpha,3beta,4alpha,5alpha)]-; (1S,3R,4R,5R)-3-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexane-1-carboxylic acid; TL8001703; [1S-(1alpha,3beta,4alpha,5alpha)]3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; NSC-407296; 3-O-(3,4-Dihydroxycinnamoyl)-D-quinic acid; Chlorogenic acid, United States Pharmacopeia (USP) Reference Standard; Hlorogenate; 3-trans-Caffeoylquinic acid; BG00688012; ACon1_000581; Chlorogenic acid, Chiral; HMS2235F03; NSC407296; J10338; ST2419179; Quinic acid, 5-caffeoyl-; CC-919; 318ADP12RI; Prestwick3_000427; EINECS 206-325-6; NCGC00168941-02; 3-o-caffeoylquinic acid ; CHEBI:95271; BIDD:ER0453; (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid; 327C979; 3-Caffeoylquinate; HY-N0055; 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate); NSC70861; (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; Cyclohexanecarboxylic acid, 3-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-1,4,5-trihydroxy-, (1S-(1-alpha,3-beta,4-alpha,5-alpha))-; CHEMBL284616; CWVRJTMFETXNAD-JUHZACGLSA-N; 5-CQA; NSC 70861; (1S,3R,4R,5R)-3-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)-1,4,5-trihydroxycyclohexane-1-carboxylic acid; bmse000387; Hlorogenic acid; LS-1202; SCHEMBL19466; (1R,3S,4S,5S)-3-[(E)-3-(3,4-Dihydroxy-phenyl)-acryloyloxy]-1,4,5-trihydroxy-cyclohexanecarboxylic acid; MolPort-001-740-212; Chlorogenic acid (constituent of st. john's wort) [DSC]; RL03176; Chlorogenic acid, primary pharmaceutical reference standard; AS-12284; MFCD00003862; 3-CQA; NSC-70861; Spectrum5_000733; D02HCQ; DB12029; SR-01000841185-4; HMS2096E16; s2280; Cyclohexanecarboxylic acid, 3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-, (1S,3R,4R,5R)-; SC-13943; HMS3649E06; Chlorogenic acid, >=95% (titration); I04-11738; 5-caffeoyl quinic acid; 3-O-caffeoyl quinic acid; CS-3766; Caffeoyl quinic acid; Chlorogenicacid; BSPBio_003353; BDBM50327036; BC202916; NSC 407296; HMS1569E16; caffeoylquinic acid; CP chlorogenic acid; 1,3,4,5-Tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate; 3-O-caffeoyl-D-quinic acid; trans-Caffeic acid 5-o-D-quinate; (1S,3R,4R,5R)-3-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)-1,4,5-trihydroxycyclohexanecarboxylic acid; Heriguard; 5-O-(3,4-Dihydroxycinnamoyl)-L-quinic acid; cyclohexanecarboxylic acid, 3-[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-, (1S,3R,4R,5R)-; Prestwick_112; 3-(3,4-Dihydroxycinnamoyl)quinic acid; BRD-K47114202-001-06-2; D54CAE3D-CDDA-455D-A28E-77FC9EFE4A43; BSPBio_000414; 327-97-9; CC0158; K-7597; 3-o-caffeoylquinic acid; caffetannic acid;caffeoylquinic acid ; 3- caffeoylquinic acid; 4-o-caffeoyl-d-quinic acide; [3-4] Chlorogenic acid; Chlorgenic acid; 4-o-caffeoyl-d-quinic acide; 5-caffeoylquinic acid; isochlorogenic acid; 5-Dicaffeoylquinic acid; isochlorogenic acid a; 5-o-caffeoylquinic acid; (1R,3R,4S,5R)-3-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; (1R,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxy-cyclohexane-1-carboxylic acid; 5-o-caffeoylquinic acid ; 5-Caffeylquinic acid; trans-5-O-caffeoyl-D-quinic acid; 5- O- caffeoylquinicacid; (1R,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid; ACon1_000392; 5- o -caffeoylquinic acid; (1R,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)-1-oxoprop-2-enoxy]-1,4,5-trihydroxy-1-cyclohexanecarboxylic acid; 1D-[1(OH),3,4/5]-3-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxycyclohexanecarboxylic acid; 906-33-2; Cyclohexanecarboxylic acid, 3-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-1,4,5-trihydroxy-, (1R-(1alpha,3alpha,4alpha,5beta))-; (1R,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)acryloyl]oxy-1,4,5-trihydroxy-cyclohexane-1-carboxylic acid; (1R-(1alpha,3alpha,4alpha,5beta))-3-((3-(3,4-Dihydroxyphenyl)-1-oxoallyl)oxy)-1,4,5-trihydroxycyclohexanecarboxylic acid; CHEBI:16384; EINECS 212-997-1; 3-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexane-1-carboxylic acid; BIB6027; 3-{[3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexane-1-carboxylic acid; NSC-407297; AKOS022146313; neochlorogenicacid; CWVRJTMFETXNAD-DUXPYHPUSA-N; BDBM153327; 3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxy-cyclohexanecarboxylic acid; 5-[[3-(3,4-Dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,3,4-trihydroxycyclohexanecarboxylic acid; neo-chlorogenic,acid; 3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid; STL377917; 5-caffeoylquinic acid; neo-chlorogenic acid; NSC407297; ZX-AT010530; Isochlorogenic acid; 5-O-caffeoyl quinic acid; 5Z-Caffeoylquinic acid; AC1NSTIZ; BBL028113; OR1166; BPH-1068; 534-61-2; SCHEMBL1228850; MolPort-001-759-169; neochlorogenic acid; 3-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid; Neochlorogenic acid; isochlorogenic acid; isochlorogenicacid; ZINC3947476; NCGC00142471-01; NCGC00017241-02; AKOS025402181; CHEMBL1552319; AC-6051; chorogenic acid; 1,3-caffeoylquinic acid | C16H18O9 | 354.31g/mol | C1C(C(C(CC1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O |
| TCMBANKIN059438 | 2-methoxy-4-propenyl phenol | C10H12O2 | 164.2 g/mol | CC=CC1=CC(=C(C=C1)O)OC | |
| TCMBANKIN059917 | methylbenzol | C6H5CH3 | 92.14 g/mol | CC1=CC=CC=C1 | |
| TCMBANKIN060702 | EPA | C20H30O2 | 302.45 | CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O | |
| TCMBANKIN060704 | (z,z,z)-9,12,15-octadecatrienoic acid | C18H30O2 | 278.4 g/mol | CCC=CCC=CCC=CCCCCCCCC(=O)O | |
| TCMBANKIN061207 | Di-n-butyl phthalate | C16H22O4 | 278.34 g/mol | CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC | |
| TCMBANKIN061948 | iodin | iodine | I2 | 253.8089 g/mol | II |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000023 | Skin and Connective Tissue Diseases; Immune System Diseases | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI000066 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI000088 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | group | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000673 | Respiratory Tract Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI003215 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI004857 | Nervous System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI005557 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007618 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | phenotype | |
| TCMBANKDI007832 | Cardiovascular Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI009278 | Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI009773 | Pathological Conditions, Signs and Symptoms; Immune System Diseases; Hemic and Lymphatic Diseases | Abnormality of the immune system; Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI010063 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI010565 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI010939 | Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases; Behavior and Behavior Mechanisms; Cardiovascular Diseases | - | Congenital Abnormality | disease | |
| TCMBANKDI011032 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011645 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI012012 | Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI013148 | Respiratory Tract Diseases; Nervous System Diseases | Abnormality of the nervous system; Abnormality of the respiratory system | Disease or Syndrome | disease | |
| TCMBANKDI013495 | Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI013546 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI014688 | Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | phenotype | |
| TCMBANKDI014839 | Nutritional and Metabolic Diseases; Immune System Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015144 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI015452 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI015491 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases; Nervous System Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015757 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI016026 | Neoplasms; Eye Diseases | Neoplasm; Abnormality of the eye | Neoplastic Process | disease | |
| TCMBANKDI016263 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI016612 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | phenotype | |
| TCMBANKDI016720 | - | - | Finding | phenotype | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017290 | Neoplasms; Endocrine System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017381 | Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI017467 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI018245 | Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI018565 | Nutritional and Metabolic Diseases; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI018680 | Eye Diseases; Immune System Diseases; Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI018862 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI019267 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Sign or Symptom | phenotype | |
| TCMBANKDI019307 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI020527 | Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI020574 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Stomatognathic Diseases | Abnormality of the nervous system; Abnormality of head or neck; Abnormality of the musculature | Disease or Syndrome | disease | |
| TCMBANKDI020792 | Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI021455 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI023140 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI023464 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI023582 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI023751 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI023834 | Nervous System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI023938 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024935 | Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | phenotype | |
| TCMBANKDI025141 | Endocrine System Diseases | Abnormality of the endocrine system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI030041 | Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI030411 | Digestive System Diseases | Abnormality of the digestive system | Finding | phenotype | |
| TCMBANKDI031189 | Neoplasms | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI031570 | - | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI031582 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Endocrine System Diseases | - | Disease or Syndrome; Congenital Abnormality | disease | |
| TCMBANKDI032163 | Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI032222 | Nervous System Diseases; Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI032498 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease |
滇IICP备16009434号-1 |
Dai SX Lab